OIM
ACAD icon

Oracle Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Oracle Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-459,300
Closed -$1.06M – 30
2022
Q1 		$1.06M Buy
+459,300
New +$11.1M 0.21% 23

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oracle Investment Management's ACAD Position: Q2 2022 in Review

Oracle Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 186,789 shares — an estimated $3.49M sold.

Oracle Investment Management first reported a position in ACAD in Q1 2022 and held it in 1 quarter. The position peaked at $4.52M in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Oracle Investment Management reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Oracle Investment Management sold 186,789 Acadia Pharmaceuticals shares in Q2 2022, an estimated $3.49M.
  • Oracle Investment Management first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Oracle Investment Management's Acadia Pharmaceuticals position peaked at $4.52M in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Oracle Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.